Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 441 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve 1. To consider and approve ....
Regulatory Filings Classification · 85% confidence The document is a formal announcement to the stock exchange under SEBI Listing Regulations informing about the postponement and rescheduling of a Board of Directors meeting. It does not present financial results itself, nor is it a management change notice, call transcript, or any other specific report. There is no specific category for board meeting notices, so this falls into the general regulatory announcement bucket. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-29 English
Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve 1. To consider and approve the ....
Regulatory Filings Classification · 82% confidence The document is an intimation of the date of a Board of Directors meeting under SEBI LODR Regulation 29. It does not present financial results or substantive content itself but merely notifies the company’s regulator and exchange of the meeting date and agenda. It is not a full annual or interim report, nor an earnings release, call transcript, or change in management. Therefore it falls under the general regulatory announcements category (fallback).
2026-05-25 English
please find enclosed
Regulatory Filings Classification · 92% confidence The document is an Annual Secretarial Compliance Report prepared by an external Company Secretary in Practice under SEBI LODR Regulation 24A. It is a statutory compliance certificate and attestation rather than a financial performance report or investor presentation. Per the certification rule, officer certifications and compliance confirmations fall under Regulatory Filings (RNS), not a substantive financial report category.
2026-05-19 English
please find enclosed
Regulatory Filings Classification · 85% confidence The document is a notice to the stock exchange forwarding a compliance report received from the Registrar and Share Transfer Agent regarding re-lodgement of transfer requests for physical shares as required under a SEBI circular. It is not an AGM presentation, financial report, earnings release, capital issuance, shareholding disclosure, M&A, dividend notice, or any other more specific category. It is a general regulatory compliance filing and thus falls under Regulatory Filings (RNS).
2026-05-11 English
please find enclosed
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange and company secretary regarding the re-lodgement of transfer requests of physical shares, referencing a SEBI circular. It contains no financial statements, no management discussion, no earnings data, or other report content. The document is a regulatory communication providing information for record-keeping and compliance purposes. It is short (2376 characters) and serves as an informational filing rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-13 English
please find enclosed
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, covering the period from January 1, 2026 to March 31, 2026. It is a compliance certificate from the Registrar and Transfer Agent confirming actions related to dematerialization of securities. The document is addressed to the stock exchange and is a regulatory compliance filing rather than a financial report or announcement of financial results. It does not contain financial statements or management discussion, nor is it an announcement of voting results or capital changes. It is primarily a regulatory compliance certificate, which fits best under Regulatory Filings (RNS) as per the classification rules, especially since it is a certification and compliance document rather than a report or announcement of a report.
2026-04-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.